Targeting DNA double-strand break repair pathways to improve radiotherapy response
M Toulany - Genes, 2019 - mdpi.com
More than half of cancer patients receive radiotherapy as a part of their cancer treatment.
DNA double-strand breaks (DSBs) are considered as the most lethal form of DNA damage …
DNA double-strand breaks (DSBs) are considered as the most lethal form of DNA damage …
Locally advanced, unresectable non-small cell lung cancer
Abstract Purpose of Review Treatment of locally advanced, unresectable non-small cell lung
cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to …
cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to …
Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer
R Komaki, PK Allen, X Wei, GR Blumenschein… - International Journal of …, 2015 - Elsevier
Purpose To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …
[HTML][HTML] Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
N Wang, L Wang, X Meng, J Wang… - Oncology …, 2019 - spandidos-publications.com
Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with …
tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with …
Treatment-related pneumonitis of EGFR tyrosine kinase inhibitors plus thoracic radiation therapy in patients with non-small cell lung cancer: a systematic review and …
Y Meng, H Sun, S Wang, H Yang - International Journal of Radiation …, 2023 - Elsevier
Thoracic radiation therapy (RT) for non-small cell lung cancers may overcome resistance to
tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis …
tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis …
[PDF][PDF] A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer
XP Zhu, YH Xu, J Zhou, XF Pan - Genet Mol Res, 2015 - funpecrp.com.br
To compare the efficacy of dendritic and cytokineinduced killer cells (DC-CIK) therapy
combined with concurrent radiochemotherapy on stage IIIB non-small cell lung cancer …
combined with concurrent radiochemotherapy on stage IIIB non-small cell lung cancer …
Treatment-related pneumonitis of EGFR tyrosine kinase inhibitors plus thoracic radiotherapy in patients with non-Small cell lung cancer: a systematic review and meta …
Y Meng, H Sun, S Wang, H Yang - International Journal of …, 2023 - redjournal.org
Introduction Thoracic radiotherapy (RT) for non-small cell lung cancers (NSCLCs) may
overcome resistance to tyrosine kinase inhibitors (TKIs). However, the risk of severe …
overcome resistance to tyrosine kinase inhibitors (TKIs). However, the risk of severe …
Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?
B Jeremić, E Mariamidze, I Shoshiashvili, I Kiladze - Current Oncology, 2022 - mdpi.com
Background: Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT)
and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung …
and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung …
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer
D Marquez-Medina, S Popat - Future Oncology, 2016 - Taylor & Francis
Nonadvanced non-small-cell lung cancer (NSCLC) has a poor long-term survival from
surgery or definitive radiation that is minimally improved with induction/adjuvant …
surgery or definitive radiation that is minimally improved with induction/adjuvant …
EGFR 抑制剂对肿瘤的抑制和放疗增敏作用研究进展
陈扬, 赵路军 - 中国肿瘤临床, 2015 - cjco.cn
放射治疗是治疗肿瘤的重要手段, 提高放疗疗效仍是目前肿瘤放射治疗学领域亟待解决的难题.
表皮生长因子受体(epidermal growth factor receptor, EGFR) 是ErbB 家族成员之一 …
表皮生长因子受体(epidermal growth factor receptor, EGFR) 是ErbB 家族成员之一 …